Citigroup Inc. upgraded shares of Horizon Pharma Inc. (NASDAQ:HZNP) from a neutral rating to a buy rating in a research note issued to investors on Monday.

Other research analysts have also recently issued reports about the company. Mizuho reaffirmed a buy rating and set a $30.00 price objective (up from $24.00) on shares of Horizon Pharma in a research report on Wednesday, August 10th. Brean Capital reaffirmed a buy rating and set a $30.00 price objective on shares of Horizon Pharma in a research report on Tuesday, August 9th. Morgan Stanley set a $24.00 price objective on Horizon Pharma and gave the stock a hold rating in a research report on Monday, September 12th. BMO Capital Markets reaffirmed an outperform rating and set a $30.00 price objective on shares of Horizon Pharma in a research report on Tuesday, September 13th. Finally, Zacks Investment Research cut Horizon Pharma from a buy rating to a hold rating in a research report on Thursday, August 11th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating, ten have given a buy rating and one has issued a strong buy rating to the stock. The company currently has an average rating of Buy and a consensus target price of $29.62.

Analyst Recommendations for Horizon Pharma (NASDAQ:HZNP)

Shares of Horizon Pharma (NASDAQ:HZNP) opened at 21.18 on Monday. The firm’s market capitalization is $3.42 billion. Horizon Pharma has a 12-month low of $13.05 and a 12-month high of $23.44. The company’s 50-day moving average price is $18.75 and its 200 day moving average price is $18.60.

Horizon Pharma (NASDAQ:HZNP) last released its quarterly earnings data on Monday, November 7th. The biopharmaceutical company reported $0.70 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.63 by $0.07. The business earned $273.70 million during the quarter, compared to analysts’ expectations of $270.04 million. Horizon Pharma had a positive return on equity of 22.73% and a negative net margin of 1.34%. The business’s quarterly revenue was up 20.8% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.70 EPS. On average, equities research analysts forecast that Horizon Pharma will post $2.02 EPS for the current fiscal year.

WARNING: “Horizon Pharma Inc. (HZNP) Upgraded by Citigroup Inc. to Buy” was first reported by Daily Political and is owned by of Daily Political. If you are reading this news story on another domain, it was stolen and republished in violation of US and international trademark & copyright legislation. The correct version of this news story can be viewed at http://www.dailypolitical.com/2016/11/29/horizon-pharma-inc-hznp-upgraded-by-citigroup-inc-to-buy.html.

Institutional investors have recently added to or reduced their stakes in the company. Quantbot Technologies LP acquired a new position in Horizon Pharma during the third quarter valued at about $112,000. Societe Generale acquired a new position in Horizon Pharma during the second quarter valued at about $117,000. SG Americas Securities LLC acquired a new position in Horizon Pharma during the second quarter valued at about $117,000. Nuveen Asset Management LLC acquired a new position in Horizon Pharma during the second quarter valued at about $176,000. Finally, Profund Advisors LLC acquired a new position in Horizon Pharma during the second quarter valued at about $194,000. Institutional investors own 86.91% of the company’s stock.

About Horizon Pharma

Horizon Pharma plc, formerly Vidara Therapeutics International Public Limited Company, is a biopharmaceutical company. The Company is focused on identifying, developing, acquiring or in-licensing and commercializing differentiated products. It markets approximately nine medicines through its orphan, primary care and rheumatology business units.

5 Day Chart for NASDAQ:HZNP

Receive News & Ratings for Horizon Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Pharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.